Study analysis · The New England journal of medicine · 2026
Estrogen patches match standard prostate cancer hormone shots—but with a dramatic side-effect swap: far fewer hot flashes, far more breast growth.
For men with locally advanced prostate cancer, estrogen skin patches worked about as well as standard hormone-blocking shots at keeping cancer from spreading over 3 years, but caused fewer hot flashes and more breast tenderness.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where patients were randomly split into two groups to compare a skin patch against standard shots. It shows the patch is not worse than the shots for keeping cancer from spreading after 3 years. But because we only have a summary, we can't be 100% sure about all the details.
What’s the bottom line?
Doctors tested whether estrogen patches work as well as standard hormone shots for treating advanced prostate cancer. They gave 1360 men either estrogen patches or standard LHRH agonist shots. After 3 years, the patches were just as good at keeping cancer from spreading, but men on patches had fewer hot flashes and more breast tenderness.
How strong is this study?
The study is a large, well-run randomized trial, which is one of the best ways to compare treatments. However, we don't know if patients knew which treatment they got, which could affect how they report side effects. Also, we only read the summary, not the full details, so some uncertainty remains.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=1360)+20.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 568 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is explicitly described as a phase 3 randomized noninferiority trial, so randomization allows causal inference for the comparison. However, full methodology is not available (abstract only), blinding is unknown, and the noninferiority design supports claims of 'not worse' rather than superiority. Causal claims are limited to the noninferiority conclusion and observed differences in side effects; superiority claims are not supported.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; study funded by non-profit organizations with no industry involvement.
Funders
Abstract does not contain a competing interests section. No author affiliations or industry ties are provided. Funding sources are non-commercial.
Key takeaways
- 01
After 3 years, 87.1% of men on patches and 85.9% on shots had no cancer spread (absolute difference 1.2 percentage points, or about 12 fewer cases per 1000 men).
- 02
After 5 years, 81.1% on patches and 79.2% on shots were alive (absolute difference 1.9 percentage points, or about 19 fewer deaths per 1000 men).
- 03
Hot flashes: 44% on patches vs 89% on shots (absolute difference 45 percentage points).
- 04
Breast tenderness: 85% on patches vs 42% on shots (absolute difference 43 percentage points).
- 05
The main result is that estrogen patches are not worse than standard shots for preventing cancer spread.
- 06
The absolute difference is small: about 12 fewer men per 1000 had cancer spread with patches over 3 years.
- 07
But the side effects are very different: patches caused far fewer hot flashes (450 fewer per 1000 men) but far more breast tenderness (430 more per 1000 men).
- 08
So the choice depends on which side effects matter more to the patient.
Practical takeaways
For patients with locally advanced prostate cancer, tE2 patches may be a reasonable alternative to LHRH agonists, but the choice should weigh fewer hot flashes against more gynecomastia.
Based on abstract only; full methodology not verifiable. The study has corrections/errata. Individual results may vary and treatment decisions should be made with a clinician.
low confidenceAsk your doctor about the full side-effect profile of different androgen-deprivation therapy options, including hot flashes and breast tissue changes.
Abstract does not specify management strategies for gynecomastia or hot flashes, nor patient-reported quality-of-life measures.
low confidenceWhy this study matters
Estrogen patches are noninferior for cancer control
In 1,360 men with locally advanced prostate cancer, 3-year metastasis-free survival was 87.1% with transdermal estradiol (tE2) patches vs 85.9% with LHRH agonists. The absolute difference was 1.2 percentage points (about 12 fewer events per 1,000 patients over 3 years), and the relative hazard ratio was 0.96, with the upper limit of the one-sided 95% CI at 1.11—within the prespecified 4-percentage-point noninferiority margin.
This offers a potentially effective alternative to standard hormone injections, which many patients find burdensome.
The side-effect trade-off: fewer hot flashes, more gynecomastia
Hot flashes occurred in 44% of tE2 users vs 89% of LHRH agonist users (absolute difference 45 percentage points); grade ≥2 hot flashes were 8% vs 37%. However, gynecomastia occurred in 85% vs 42% (absolute difference 43 percentage points); grade ≥2 gynecomastia was 37% vs 9%.
Side effects strongly affect quality of life, and patients may prioritize avoiding hot flashes or breast growth differently.
Testosterone suppression was similar
Among patients continuing assigned treatment, castrate testosterone levels (<1.7 nmol/L) were sustained during the first year after randomization in about 85% of both groups.
It shows the patch achieves the same hormonal goal as LHRH agonists, supporting the biological rationale.
Overall survival similar at 5 years
Observed 5-year overall survival was 81.1% with tE2 vs 79.2% with LHRH agonists, an absolute difference of 1.9 percentage points (about 19 fewer deaths per 1,000 over 5 years); the relative hazard ratio for death was 0.90 (95% CI, 0.75 to 1.07), which includes no difference.
Long-term survival is the ultimate concern, and these numbers are reassuring but not definitive.
Important caveats: abstract only and corrections published
The full text was not available for this analysis, and the study has published corrections/errata. Blinding status is not specified in the abstract. These factors limit confidence in the details.
Transparency about study limitations is crucial for accurate science communication.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors tested whether estrogen patches work as well as standard hormone shots for treating advanced prostate cancer. They gave 1360 men either estrogen patches or standard LHRH agonist shots. After 3 years, the patches were just as good at keeping cancer from spreading, but men on patches had fewer hot flashes and more breast tenderness.
Research results
After 3 years, 87.1% of men on patches and 85.9% on shots had no cancer spread (absolute difference 1.2 percentage points, or about 12 fewer cases per 1000 men). After 5 years, 81.1% on patches and 79.2% on shots were alive (absolute difference 1.9 percentage points, or about 19 fewer deaths per 1000 men). Hot flashes: 44% on patches vs 89% on shots (absolute difference 45 percentage points). Breast tenderness: 85% on patches vs 42% on shots (absolute difference 43 percentage points).
What this means - more context
The main result is that estrogen patches are not worse than standard shots for preventing cancer spread. The absolute difference is small: about 12 fewer men per 1000 had cancer spread with patches over 3 years. But the side effects are very different: patches caused far fewer hot flashes (450 fewer per 1000 men) but far more breast tenderness (430 more per 1000 men). So the choice depends on which side effects matter more to the patient.
To compare transdermal estradiol (tE2) patches with luteinizing hormone-releasing hormone (LHRH) agonists as androgen-deprivation therapy in men with locally advanced prostate cancer.
In this phase 3 noninferiority randomized trial, tE2 patches were noninferior to LHRH agonists for 3-year metastasis-free survival (87.1% vs 85.9%, absolute difference 1.2 percentage points; HR 0.96, upper limit one-sided 95% CI 1.11). tE2 resulted in lower rates of hot flashes (44% vs 89%; grade ≥2: 8% vs 37%) but higher rates of gynecomastia (85% vs 42%; grade ≥2: 37% vs 9%). Castrate testosterone levels were sustained in 85% of both groups. 5-year overall survival was similar (81.1% vs 79.2%; HR 0.90, 95% CI 0.75-1.07). Note: This study has published corrections/errata; readers should check the correction notices for updated information.
Methods Used
Phase 3, noninferiority, randomized trial conducted at 75 U.K. centers. 1360 men with locally advanced (M0 and N0 or N+) prostate cancer were assigned to tE2 patches (100 μg every 24 hours) or LHRH agonists. Primary outcome was 3-year metastasis-free survival; noninferiority margin was 4 percentage points. Secondary outcomes included castrate testosterone levels, overall survival, and safety.
Main Finding
tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival: 87.1% vs 85.9% (absolute difference 1.2 percentage points; about 12 fewer events per 1000 patients over 3 years; HR 0.96, upper limit one-sided 95% CI 1.11). 5-year overall survival was 81.1% vs 79.2% (absolute difference 1.9 percentage points; about 19 fewer deaths per 1000 over 5 years; HR 0.90, 95% CI 0.75-1.07). tE2 caused fewer hot flashes (44% vs 89%; absolute difference 45 percentage points) but more gynecomastia (85% vs 42%; absolute difference 43 percentage points).
Confidence Level
Limited - based on abstract only, full methodology not available. The study has published corrections/errata that should be consulted.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has published corrections/errata; check for updated information
- •Blinding status not specified in abstract
Practical Takeaways
For patients with locally advanced prostate cancer, tE2 patches may be a reasonable alternative to LHRH agonists, but the choice should weigh fewer hot flashes against more gynecomastia.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 568 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a fair test where patients were randomly split into two groups to compare a skin patch against standard shots. It shows the patch is not worse than the shots for keeping cancer from spreading after 3 years. But because we only have a summary, we can't be 100% sure about all the details.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized controlled trial design (phase 3).
- Large sample size (n=1360).
- Multicenter (75 U.K. centers).
Weaknesses
- Full methodology not available - based on abstract only.
- Blinding status unknown.
- Noninferiority design does not test superiority.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors tested whether estrogen patches work as well as standard hormone shots for treating advanced prostate cancer. They gave 1360 men either estrogen patches or standard LHRH agonist shots. After 3 years, the patches were just as good at keeping cancer from spreading, but men on patches had fewer hot flashes and more breast tenderness.
Research results
After 3 years, 87.1% of men on patches and 85.9% on shots had no cancer spread (absolute difference 1.2 percentage points, or about 12 fewer cases per 1000 men). After 5 years, 81.1% on patches and 79.2% on shots were alive (absolute difference 1.9 percentage points, or about 19 fewer deaths per 1000 men). Hot flashes: 44% on patches vs 89% on shots (absolute difference 45 percentage points). Breast tenderness: 85% on patches vs 42% on shots (absolute difference 43 percentage points).
What this means - more context
The main result is that estrogen patches are not worse than standard shots for preventing cancer spread. The absolute difference is small: about 12 fewer men per 1000 had cancer spread with patches over 3 years. But the side effects are very different: patches caused far fewer hot flashes (450 fewer per 1000 men) but far more breast tenderness (430 more per 1000 men). So the choice depends on which side effects matter more to the patient.
To compare transdermal estradiol (tE2) patches with luteinizing hormone-releasing hormone (LHRH) agonists as androgen-deprivation therapy in men with locally advanced prostate cancer.
In this phase 3 noninferiority randomized trial, tE2 patches were noninferior to LHRH agonists for 3-year metastasis-free survival (87.1% vs 85.9%, absolute difference 1.2 percentage points; HR 0.96, upper limit one-sided 95% CI 1.11). tE2 resulted in lower rates of hot flashes (44% vs 89%; grade ≥2: 8% vs 37%) but higher rates of gynecomastia (85% vs 42%; grade ≥2: 37% vs 9%). Castrate testosterone levels were sustained in 85% of both groups. 5-year overall survival was similar (81.1% vs 79.2%; HR 0.90, 95% CI 0.75-1.07). Note: This study has published corrections/errata; readers should check the correction notices for updated information.
Methods Used
Phase 3, noninferiority, randomized trial conducted at 75 U.K. centers. 1360 men with locally advanced (M0 and N0 or N+) prostate cancer were assigned to tE2 patches (100 μg every 24 hours) or LHRH agonists. Primary outcome was 3-year metastasis-free survival; noninferiority margin was 4 percentage points. Secondary outcomes included castrate testosterone levels, overall survival, and safety.
Main Finding
tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival: 87.1% vs 85.9% (absolute difference 1.2 percentage points; about 12 fewer events per 1000 patients over 3 years; HR 0.96, upper limit one-sided 95% CI 1.11). 5-year overall survival was 81.1% vs 79.2% (absolute difference 1.9 percentage points; about 19 fewer deaths per 1000 over 5 years; HR 0.90, 95% CI 0.75-1.07). tE2 caused fewer hot flashes (44% vs 89%; absolute difference 45 percentage points) but more gynecomastia (85% vs 42%; absolute difference 43 percentage points).
Confidence Level
Limited - based on abstract only, full methodology not available. The study has published corrections/errata that should be consulted.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Study has published corrections/errata; check for updated information
- •Blinding status not specified in abstract
Practical Takeaways
For patients with locally advanced prostate cancer, tE2 patches may be a reasonable alternative to LHRH agonists, but the choice should weigh fewer hot flashes against more gynecomastia.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 568 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a fair test where patients were randomly split into two groups to compare a skin patch against standard shots. It shows the patch is not worse than the shots for keeping cancer from spreading after 3 years. But because we only have a summary, we can't be 100% sure about all the details.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized controlled trial design (phase 3).
- Large sample size (n=1360).
- Multicenter (75 U.K. centers).
Weaknesses
- Full methodology not available - based on abstract only.
- Blinding status unknown.
- Noninferiority design does not test superiority.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is a large, well-run randomized trial, which is one of the best ways to compare treatments. However, we don't know if patients knew which treatment they got, which could affect how they report side effects. Also, we only read the summary, not the full details, so some uncertainty remains.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=1360)+20.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 568 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is explicitly described as a phase 3 randomized noninferiority trial, so randomization allows causal inference for the comparison. However, full methodology is not available (abstract only), blinding is unknown, and the noninferiority design supports claims of 'not worse' rather than superiority. Causal claims are limited to the noninferiority conclusion and observed differences in side effects; superiority claims are not supported.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; study funded by non-profit organizations with no industry involvement.
Funders
Abstract does not contain a competing interests section. No author affiliations or industry ties are provided. Funding sources are non-commercial.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
52 researchersIf this is your work, this is how we attribute it on Fit Body Science. R. Langley is listed as the lead author.